



COPY OF PAPER
ORIGINALLY FILED

AF
1600

Please type a plus sign (+) inside this box →



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/716,842	
		Filing Date	November 17, 2000	
		First Named Inventor	BRIESEWITZ, ROGER	
		Group Art Unit	1644	
		Examiner Name	HUYNH, PHUONG NEON	
Total Number of Pages in This Submission		8	Attorney Docket Number	STAN-131
ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____		<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return receipt postcard
Remarks				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm or Individual Name	BRET E. FIELD, Reg. No. 37,620			
Signature				
Date	August 5, 2002			

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: August 5, 2002.			
Typed or printed name	Donna Macedo		
Signature		Date	August 5, 2002

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Donna Macedo		
Signature	D. Macedo	Date	8/5/02

AMENDMENT AND RESPONSE TO PAPER NO. 10 Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket Confirmation No.	STAN-131
	First Named Inventor	Crabtree
	Application Number	09/716,842
	Filing Date	November 17, 2000
	Group Art Unit	1644
	Examiner Name	P. Huynh
	Title	TARGETED BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON

Dear Sir:

In response to the FINAL REJECTION dated May 7, 2002, please enter the following amendments:

AMENDMENTS

In the claims:

16. (Amended) A method for directing the biodistribution of a drug to an intracellular space upon administration to a host, said method comprising:

administering to said mammalian host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a targeting moiety that is an intracellular biodistribution modulating protein optionally joined by a linking group, wherein said bifunctional molecule has a modulated biodistribution upon administration to said host as compared to a free drug control;

whereby said biodistribution of said drug upon administration to said host is directed to an intracellular space as compared to a free drug control.